Skip to main content
Log in

ESC/EACTS-Leitlinien zur Myokardrevaskularisation 2018

Die wichtigsten Neuerungen

ESC/EACTS guidelines on myocardial revascularization 2018

The most important innovations

  • Schwerpunkt
  • Published:
Herz Aims and scope Submit manuscript

Zusammenfassung

Die 2018 erschienenen Leitlinien zur Myokardrevaskularisation sind eine gemeinsame Initiative der Europäischen Gesellschaft für Kardiologie und der Europäischen Assoziation für Herz- und Thoraxchirurgie. Für die Indikation zur Myokardrevaskularisation durch perkutane Koronarintervention (PCI) oder koronare Bypassoperation (CABG) ist ein Nachweis der funktionellen Relevanz von Koronarstenosen durch bildgebende nicht-invasive Funktionstests oder intravaskuläre hämodynamische Messungen erforderlich. Der prognostische und symptomatische Nutzen der Myokardrevaskularisation hängt davon ab, ob eine komplette Revaskularisation erzielt werden kann. Dies ist bei der Wahl des geeigneten Revaskularisationsverfahrens zu berücksichtigen. Daneben sind das individuelle operative Risiko, die technische Machbarkeit, das Vorliegen eines Diabetes mellitus sowie die anatomische Komplexität des Koronarbefalls, quantifiziert mit dem SYNTAX-Score, entscheidende Kriterien in der Wahl des optimalen Revaskularisationsverfahrens. Für die PCI werden der radiale Gefäßzugang und die generelle Verwendung von Drug-eluting-Stents empfohlen. Für die CABG sind multiple arterielle Grafts anzustreben, einschließlich der Arteria radialis zur Behandlung hochgradiger Koronarstenosen.

Abstract

The guidelines on myocardial revascularization published in 2018 are a joint initiative of the European Society of Cardiology and the European Association for Cardio-Thoracic Surgery. To establish indications for myocardial revascularization by percutaneous coronary intervention (PCI) or coronary artery bypass grafting (CABG), evidence of the functional relevance of coronary artery stenoses is needed either by non-invasive imaging function tests or intravascular hemodynamic measurements. The prognostic and symptomatic benefits of myocardial revascularization depend on whether complete revascularization can be achieved. This needs to be considered when choosing the most appropriate revascularization strategy. In addition, the individual operative risk, the technical feasibility, the presence of diabetes mellitus and the anatomical complexity of coronary artery disease, as assessed by the SYNTAX score, are key criteria when choosing the optimal method of revascularization. For PCI radial artery access and the general use of drug-eluting stents are recommended. For CABG multiple arterial grafts should be strived for including the radial artery for treatment of high-grade coronary stenosis.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Abb. 1
Abb. 2
Abb. 3

Literatur

  1. Neumann FJ, Sousa-Uva M, Ahlsson A et al (2018) 2018 ESC/EACTS guidelines on myocardial revascularization. Eur Heart J. https://doi.org/10.1093/eurheartj/ehy394

    Article  PubMed  Google Scholar 

  2. Garcia S, Sandoval Y, Roukoz H et al (2013) Outcomes after complete versus incomplete revascularization of patients with multivessel coronary artery disease: a meta-analysis of 89,883 patients enrolled in randomized clinical trials and observational studies. J Am Coll Cardiol 62:1421–1431

    Article  PubMed  Google Scholar 

  3. Head SJ, Milojevic M, Daemen J et al (2018) Mortality after coronary artery bypass grafting versus percutaneous coronary intervention with stenting for coronary artery disease: a pooled analysis of individual patient data. Lancet 391:939–9484

    Article  PubMed  Google Scholar 

  4. Head SJ, Papageorgiou G, Milojevic M et al (2018) Interpretation of results of pooled analysis of individual patient data—authors’ reply. Lancet 392:818

    Article  PubMed  Google Scholar 

  5. Windecker S, Neumann FJ, Juni P et al (2018) Considerations for the choice between coronary artery bypass grafting and percutaneous coronary intervention as revascularization strategies in major categories of patients with stable multivessel coronary artery disease: an accompanying article of the task force of the 2018 ESC/EACTS guidelines on myocardial revascularization. Eur Heart J. https://doi.org/10.1093/eurheartj/ehy532

    Article  PubMed  Google Scholar 

  6. Thiele H, Akin I, Sandri M et al (2017) PCI strategies in patients with acute myocardial infarction and cardiogenic shock. N Engl J Med 377:2419–2432

    Article  Google Scholar 

  7. Velazquez EJ, Lee KL, Jones RH et al (2016) Coronary-artery bypass surgery in patients with ischemic cardiomyopathy. N Engl J Med 374:1511–1520

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  8. Valgimigli M, Bueno H, Byrne RA et al (2018) 2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS. Eur Heart J 39:213–260

    Article  PubMed  Google Scholar 

  9. Sibbing D, Aradi D, Jacobshagen C et al (2017) Guided de-escalation of antiplatelet treatment in patients with acute coronary syndrome undergoing percutaneous coronary intervention (TROPICAL-ACS): A randomised, open-label, multicentre trial. Lancet 390:1747–1757

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to F.-J. Neumann.

Ethics declarations

Interessenkonflikt

F.‑J. Neumann berichtet, dass sein Arbeitgeber Forschungsunterstützung sowie Berater- und Vortragshonorare von Daiichi Sankyo, Astra Zeneca, Sanofi-Aventis, Bayer, The Medicines Company, Bristol, Novartis, Roche, Boston Scientific, Biotronik, Medtronic, Edwards und Ferrer erhalten hat. W. Hochholzer berichtet Berater- und Vortragshonorare von AstraZeneca, Boehringer Ingelheim, Daiichi Sankyo und The Medicines Company. M. Siepe gibt an, dass kein Interessenkonflikt besteht.

Dieser Beitrag beinhaltet keine von den Autoren durchgeführten Studien an Menschen oder Tieren.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Neumann, FJ., Hochholzer, W. & Siepe, M. ESC/EACTS-Leitlinien zur Myokardrevaskularisation 2018. Herz 43, 689–694 (2018). https://doi.org/10.1007/s00059-018-4764-5

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00059-018-4764-5

Schlüsselwörter

Keywords

Navigation